Document:

Exhibit
10.19

 

THIS
NOTE HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS
NOTE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY APPLICABLE
STATE SECURITIES LAWS. NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE MAY BE SOLD OR OTHERWISE TRANSFERRED
OR PLEDGED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
OR EXCLUSION FROM THE REGISTRATION REQUIREMENTS THEREUNDER AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS.

 

	NOTE
    SUMMARY
	 
	Maturity
    Date:	July
    1,2022
	 	 
	Interest
    Rate:	10%
	 	 
	Interest
    Payable:	At
    maturity
	 	 
	Conversion
    Events:	●	Automatic
    conversion on earlier of: (i) IPO; or (ii) Private Sale by Maker of at least $2 million of a single class of equity securities
    within a 12 month period (each, a “Qualified Financing”)
	 	●	Optional
    conversion, at election of Investor, at Maturity Date
	 	 	 
	Conversion
    Price:	●	Principal
    and interest convert into equity securities sold in a Qualified Financing at a conversion price equal to the lesser of (i)
    80% of the price of securities sold in such Qualified Financing; or (ii) the price equal to the quotient of $10 million divided
    by the aggregate number of outstanding shares of Maker’s common stock as of immediately prior to the initial closing
    the Qualified Financing (assuming full conversion of all convertible and exercisable securities then outstanding, other than
    the Notes)
	 	 	 
	 	●	On
    optional conversion, principal and interest convert into equity securities of the Maker at a price equal to the quotient of
    $10 million divided by the aggregate number of outstanding shares of Maker’s common stock as of the Maturity Date (assuming
    full conversion of all convertible and exercisable securities then outstanding, other than the Notes)
	 	 	 
	Sale
    of Company Option:	In
    event of sale of the Maker, at Investor’s option: (i) the principal and all accrued interest owing on the note is converted,
    immediately prior to the sale, into common stock a price equal to the quotient of $10 million divided by the aggregate number
    of outstanding shares of Maker’s common stock as of immediately prior to the sale of Maker (assuming full conversion
    of all convertible and exercisable securities than outstanding, other than the Notes); or (ii) the Note is repayable in full
    at 125% of the principal owing on the Note plus all accrued and unpaid interest

 

    	 

    	 

    

 

	No.
    CS-A-1	$500,000

 

COVISTAT,
INC.

 

10.0%
Convertible Promissory Note

 

Section
1. General.

 

FOR
VALUE RECEIVED, Covistat, Inc., a Delaware corporation (the “Maker”). hereby promises to pay
to the order of TING TSENG AND WEI FONG CHAO FOUNDATION-, or its registered assigns (the “Investor”). the
principal sum of FIVE HUNDRED THOUSAND DOLLARS AND ZERO CENTS ($500,000) together with interest thereon at a rate equal to 10%
per annum, simple interest computed on the basis of the actual number of days elapsed and a year of 365 days. Unless earlier repaid
or converted in accordance with the terms hereof, all unpaid principal together with any then unpaid and accrued interest shall
be due and payable on July 1, 2022 (the “Maturity Date”) or (ii) when such amounts become due
and payable as a result of, and following, an Event of Default in accordance with Section 3. All payments required to be made
hereunder, if any, shall be made in such coin or currency of the United States of America as at the time of payment shall be legal
tender therein for the payment of public and private debts.

 

Section
2. Prepayment.

 

Maker
may not prepay this Note prior to the Maturity Date without the consent of the Investor.

 

Section
3. Conversion.

 

(a)
Automatic Conversion. In the event that a Qualified Financing occurs on or before the earlier of (i) the Maturity Date;
(ii) the date of repayment in full of this Note; or (iii) a Company Sale, then the outstanding principal balance of, and all accrued
and unpaid interest on, this Note shall automatically convert in whole into shares of the class of securities sold by Maker in
the Qualified Financing at a conversion price equal to the lesser of (y) 80% of the price of securities sold in such Qualified
Financing; or (z) the price equal to the quotient of $10 million (the “Valuation Cap”) divided
by the aggregate number of outstanding shares of Maker’s common stock as of immediately prior to the initial closing the
Qualified Financing (assuming full conversion of all convertible and exercisable securities then outstanding, other than the Notes).

 

For
purposes hereof: (v) a “Qualified Financing” shall mean an IPO or Private Sale; (w) an “IPO”
shall mean an underwritten public offering of Maker common stock at a fixed price immediately after which Maker’s common
stock is listed on a U.S. national securities exchange; (x) a “Private Sale” shall mean the sale, in
a transaction exempt from registration under the Securities Act of 1933, by Maker of a single class of equity securities consisting
of either common stock or a series of preferred stock that is convertible into common stock, in which Maker receives, in a single
closing or multiple closings occurring within a twelve month period, at least $2 million in gross proceeds; (y) for purposes of
determining the “gross price per share at which such class of securities were sold” in a Private Sale” the weighted
average price per share shall be used if the subject securities are sold at other than a single fixed price per share; and (z)
all securities issued by Maker pursuant to (I) stock option or other employee benefit arrangements, or (II) the conversion or
exercise of securities outstanding prior to the making of this Note, shall be excluded in determining whether a Private Sale has
occurred and shall similarly be excluded in calculation of price per share in connection with any Private Sale.

 

(b)
Optional Conversion. In the event that a Qualified Financing is not consummated prior to the Maturity Date, then, at the
election of the Investor made at least five days prior to the Maturity Date, effective upon the Maturity Date, the outstanding
principal balance and any unpaid accrued interest under this Note shall be converted into shares of common stock of Maker at a
conversion price equal to the quotient of $10 million divided by the aggregate number of outstanding shares of Maker’s common
stock as of the Maturity Date (assuming full conversion of all convertible and exercisable securities then outstanding, other
than the Notes).

 

    	-2-

    	 

    

 

(c)
Conversion Mechanics.

 

(i)
Upon the closing of a Qualified Financing or, in the event of an optional conversion pursuant to Section 3(b) of this Note, on
the Maturity Date, (A) this Note, and all accrued interest thereon, shall be immediately and automatically converted into shares
of Maker equity securities as described in Section 3(a) or 3(b), as the context requires; (B) Maker shall promptly notify the
Investor in writing, as the context requires, of the occurrence of the Qualified Financing, the conversion of the Note, the calculation
of the conversion price and the number and nature of the securities received upon conversion; and (C) the Investor shall have
no further rights under this Note other than the right to receive the securities issuable upon conversion.

 

(ii)
No fractional shares of securities shall be issued upon conversion of this Note. Fractional shares otherwise issuable on conversion
shall be rounded tip or down to the nearest whole number of shares based on normal rounding conventions. Upon conversion Of this
Note, the Investor shall surrender this Note, duly endorsed, at the principal office of Maker. At its expense, Maker shall, as
soon as practicable following conversion pursuant to Section 3 issue and deliver to the Investor a certificate or certificates
for the number of shares of securities to which the Investor shall be entitled upon such conversion (bearing such legends as are
required by applicable state and federal securities laws in the opinion of counsel to Maker).

 

(iii)
Maker shall at all times reserve and keep available, out of its authorized but unissued shares of capital stock, solely for the
purpose of effecting the conversion of this Note, such number of its shares of its capital stock as shall front time to time be
sufficient to effect the conversion of this Note.

 

	EXAMPLE:	In
    the event that (1) Maker carries out an IPO of its common stock at $10 per share after which the common stock is listed on
    the New York Stock Exchange (or Maker raises at least $2 million in a Private Sale within a 12-month period), (2) immediately
    prior to the IPO (or the first sale in the Private Sale), Maker has 5,000,000 shares outstanding and (3) the Investor holds
    a Note in the principal amount of $200,000 and having $20,000 of accrued interest; then, immediately upon closing of the IPO
    (Upon receipt of $2 million from the Private Sale), the entire $220,000 owing under the Note will automatically convert into
    shares of common stock at a conversion price of $2.00 per share (being the lesser of $8.00 [80% of IPO price] or $2.00 ($10
    million / 5,000,000 shares (i.e., the Valuation Cap)]) resulting in the issuance to the Investor of 110,000 shares
    of Maker common stock.

 

Section
4. Company Sale

 

(a)
Investor Option. In the event that a Company Sale occurs on or before the earlier of (i) the Maturity Date; (ii) the date
of repayment in full of this Note; or (iii) conversion of this Note pursuant to Section 3, then the Investor shall have the option,
at its sole election, to either:

 

(i)
Call (the “Call Option”) the Note for repayment at a price equal to the sum of (A) 125% of the principal
amount of the Note then owing, plus (B) all accrued and unpaid interest owing with respect to the Note (in aggregate, the “Call
Price”), or

 

(ii)
Convert (the “Company Sale Conversion Option”) the entire principal amount owing on the Note, together
with all accrued and unpaid interest on the Note, into common stock of Maker at a conversion price (the “Company Sale
Conversion Price”) equal to the quotient of $ 10 million divided by the aggregate number of outstanding shares of
Maker’s common stock as of immediately prior to the closing of the Company Sale (assuming full conversion of all convertible
and exercisable securities then outstanding, other than the Notes).

 

For
purposes hereof, a “Company Sale” shall mean (x) a sale by Maker of all or substantially all of its
assets; or (y) any merger or consolidation of Maker with or into any other entity (excluding any merger, consolidation or reorganization
in which the stockholders of Maker immediately prior to such transaction continue to hold at least a majority of the voting power
of the surviving entity in substantially the same proportion immediately after the transaction); or (z) any transaction or series
of related transactions to which Maker is a party in which in excess of 50% of Maker’s voting power is transferred; provided,
however, that a Company Sale shall not include any transaction or series of transactions principally for bona fide equity financing
purposes in which cash is received by Maker or indebtedness of Maker is cancelled or converted.

 

    	-3-

    	 

    

 

(b)
Company Sale Mechanics.

 

(i)
At least 5 business days prior to the anticipated closing of a Company Sale, Maker shall provide to the Investor written notice
of such proposed Company Sale, which notice shall include, (A) a description of the nature of the Company Sale, including but
not limited to a copy of written materials, if any, provided to other security holders of Maker in soliciting their approval of
the Company Sale; (B) a description of the securities or other property to be held by the Investor following the Company Sale
in the event that the Investor elects the Company Sale Conversion Option; and (C) the anticipated closing date (the “Company
Sale Date”) of the Company Sale.

 

(ii)
The Investor shall, at least 1 business day prior to the Company Sale Date, notify Maker as to whether it is electing the Call
Option or the Company Sale Conversion Option. In the event that the Investor fails to notify Maker of its election under Section
4(a), Maker shall have the right and authority to select either of such options as it, in its sole discretion, shall choose, in
which case, it shall promptly notify the Investor of its election.

 

(iii)
If the Investor elects the Call Option (or if Maker elects the Call Option pursuant to Section 4(b)(ii)), prior to, and as a condition
of, closing of the Company Sale, Maker shall pay to the Investor the Call Price, upon payment of which this Note shall be deemed
paid in full and all rights of the Investor under this Note shall terminate.

 

(iv)
If the Investor elects the Company Sale Conversion Option (or if Maker elects the Company Sale Conversion Option pursuant to Section
4(b)(ii)), (A) immediately prior to, and as a condition of, closing of the Company Sale, the principal amount owing under this
Note, together with all accrued and owing interest on this Note, shall be converted into shares of common stock of Maker at the
Company Sale Conversion Price; (B) upon closing of the Company Sale, the Investor shall (x) be entitled to such rights as may
accrue to the holders of common stock of Maker in the Company Sale; and (y) have no further rights under this Note.

 

(v)
The provisions of Sections 3(c)(ii) and (iii) shall apply to Section 4.

 

(vi)
As a condition of the Investor’s purchase of this Note, Maker shall include in any agreement pertaining to a proposed Company
Sale a requirement that the surviving company of such transaction will assume the conversion obligations under this Note and reserve
and keep available, out of its authorized but unissued shares of capital stock, solely for the purpose of effecting the conversion
of this Note, such number of shares of its capital stock as shall from time to time be sufficient to effect the conversion of
this Note.

 

Section
5. Defaults.

 

(a)
Events of Default. The occurrence of any of the following shall constitute an “Event of Default”
under this Note:

 

(i)
Maker shall fail to pay (i) when due any principal or interest payment hereof On the due date hereunder; or (ii) any other payment
required under the terms of this Note on the date due and such payment shall not have been made within five (5) days of Maker’s
receipt of Investor’s written notice to Maker of such failure to pay; or

 

(ii)
Maker shall fail to observe or perform any other covenant, obligation, condition or agreement contained in this Note (other than
those specified in Section 6(a)) and such failure shall continue for ten (10) days after written notice thereof is delivered to
Maker; or

 

    	-4-

    	 

    

 

(iii)
Maker shall (A) apply for or consent to the appointment of a receiver, trustee, liquidator or custodian of itself Or of all or
a substantial part of its property; (B) be unable, or admit in writing its inability, to pay its debts generally as they mature;
(C) make a general assignment for the benefit of its or any of its creditors; (D) be dissolved or liquidated in full or in part;
(E) commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or
its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or consent to any such relief or to
the appointment of or taking possession of its property by any official in an involuntary case or other proceeding commenced against
it; or (F) take any action for the purpose of effecting any of the foregoing; or

 

(iv)
Proceedings for the appointment of a receiver, trustee, liquidator or custodian of Maker or of all or a substantial part of the
property thereof, or an involuntary case or other proceedings seeking liquidation, reorganization or other relief with respect
to Maker or the debts thereof under any bankruptcy, insolvency or other similar law now or hereafter in effect shall be commenced
and an order for relief entered or such proceeding shall not be dismissed or discharged within thirty (30) days of commencement.

 

(b)
Rights Of Investor Upon Default. Upon the occurrence or existence of any Event of Default (other than an Event of Default
referred to in Sections 5(a)(iii) or (iv) hereof) and at any time thereafter during the continuance of such Event of Default,
the Investor may, by written notice to Maker, declare all outstanding amounts payable by Maker hereunder to be immediately due
and payable without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived, anything
contained herein to the contrary notwithstanding. Upon the occurrence or existence of any Event of Default described in Sections
5(a)(iii) or (iv) hereof, immediately and without notice, all outstanding amounts payable by Maker hereunder shall automatically
become immediately due and payable, without presentment, demand, protest or any other notice of any kind, all of which are hereby
expressly waived, anything contained herein to the contrary notwithstanding. In addition to the foregoing remedies, upon the occurrence
or existence of any Event of Default, the Investor may exercise any other right, power or remedy permitted to it by law, either
by suit in equity or by action at law, or both.

 

Section
6. Ranking.

 

This
Note is one of a series of Convertible Promissory Notes having substantially identical terms to those set forth herein, and bearing
the designation “CS-A-#” (each such Note being a “Note” and, collectively, the “Notes”).
Each of the Notes is an unsecured general obligation of Maker.

 

Section
7. Amendments.

 

This
Note may not be amended without the express written consent of both Maker and Investors holding a majority in outstanding principal
amount of all then outstanding Notes (excluding Notes held by Ensysce).

 

Section
8. Governing Law.

 

This
Note is made and delivered in, and shall be governed by and construed in accordance with the laws of the State of California (without
giving effect to principles of conflicts of laws of the State of California or any other state). Any action to enforce the terms
of this Note shall be exclusively brought in the state and/or federal courts in San Diego County, California.

 

Section
9. Notices.

 

Any
and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a) the day of transmission, if such transmission (i) is by means of email; (ii)
is completed on or before 5:00 p.m. (Eastern time); and (iii) is emailed to the address specified in this Section; (b) the next
Business Day after the date of transmission, if such notice (i) is by means of email; (ii) is completed (A) on a day that is not
a Business Day; or (B.) later than 5:00 p.m. (Eastern time) on any Business Day; and (iii) is emailed to the addressed specified
in this Section; (c) the Business Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service
with next day delivery specified; or (d) upon actual receipt by the party to whom such notice is required to be given. The address
for such notices and communications shall be as follows:

 

    	-5-

    	 

    

 

	If
    to Maker:	Covistat,
    Inc.
	 	6019
    Folsom Dr.
	 	La
    Jolla, California 92037
	 	Attn:
    Dr. Lynn Kirkpatrick
	 	Email:
    lkirkpatrick@ensysce.com

 

If
to an Investor: To the Investors address set forth on the signature page or such other address as may be designated in writing
hereafter, in the same manner, by such person.

 

Section
10. Successors and Assigns.

 

The
rights and obligations of Maker and the Investor under this Note shall be binding upon and benefit the successors, assigns, heirs,
administrators and transferees of the parties. Except as otherwise provided for herein, notwithstanding the foregoing, neither
this Note nor any of the rights, interests or obligations hereunder may be assigned, by operation of law or otherwise, in whole
or in part, by (i) Maker, without the prior written consent of the Investor; or (ii) by the Investor without the prior written
consent of Maker and subject to compliance with applicable federal and state securities laws, including such reasonable requirements
as may be determined by counsel to Maker.

 

Section
11. No Rights of Stockholders.

 

Except
as otherwise provided herein, this Note shall not entitle the Investor to any of the rights of a stockholder of Maker, including
without limitation, the right to vote, to receive dividends and other distributions, or to receive any notice of, or to attend,
meetings of stockholders or any other proceedings of Maker, unless and to the extent converted into shares of stock in accordance
with the terms hereof.

 

Section
12. Entire Agreement.

 

This
Note constitutes the full and entire understanding and agreement between the parties with regard to the subjects hereto and thereof.

 

    	-6-

    	 

    

 

IN
WITNESS WHEREOF, Maker has caused this Note to be duly executed by its duly authorized officer as of the date indicated below.

 

Date:
06/23/2020

 

	 	COVISTAT
    INC.
	 	 	 
	 	By:	/s/
    Lynn Kirkpatrick
	 	Name:	Dr.
    Lynn Kirkpatrick
	 	Title:	Chief
    Executive Officer

 

	Note
    No.	 	 
	Amount:	$500,000	 
	Investor
    Name:	TING
    TSUNG AND WEI FONG CHAO FOUNDATION	 
	Address:	 	 
	 	 	 
	Telephone
    No.:	 	 
	Email:	 	 
	 	 	 

 

    	 

    	 

    

 

Instructions
for Wire Transfers 

 

Wire
Transfer from Another Institution

 

If
you are sending funds by Wire Transfer, please include the following information on your instructions to the originating institution.

 

Wire
Information 

 

	Name
    of Bank:	 
	Address	 
	City
    and State:	 
	ABA
    Number (domestic)	 
	SWIFT
    Code (International	 
	Beneficiary
    Name:	 
	Beneficiary
    Account #	 
	Optional
    TextExhibit
10.20

 

ACTION
BY UNANIMOUS WRITTEN CONSENT

OF
THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF

ENSYSCE
BIOSCIENCES, INC.

 

The
undersigned, constituting all of the members of the Compensation Committee (the “Committee”) of the Board of
Directors of Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), pursuant to Section 141(f)
of the Delaware General Corporation Law and the Company’s Bylaws, hereby adopt the following recitals and resolutions by
written consent, effective as of the last date set forth on the signature pages hereto:

 

Compensation
Approval and Option Grant – Lynn Kirkpatrick

 

WHEREAS,
Lynn Kirkpatrick has agreed to continue in her full time service as Chief Executive Officer of the Company and, as consideration
therefore, the Company has agreed to grant to Dr. Kirkpatrick a stock option and to pay salary to Dr. Kirkpatrick subject to the
receipt by the Company, as measured from and after the date hereof, of certain minimum aggregate funding, in the form of either
new debt or new equity, from persons other than Bob Gower and Will Chang or their affiliates (such funding being referred to as
“Qualifying Funding”); and

 

WHEREAS,
the Committee desires to evidence its approval of the compensation arrangements negotiated with Dr. Kirkpatrick.

 

NOW,
THEREFORE, be it, and it is hereby:

 

RESOLVED,
that, Committee, having reviewed the price at which the Company’s common stock has been sold in recent transactions, has
determined that $0.212 per share is the current fair market value of the Company’s common stock;

 

RESOLVED
FURTHER, that an option (the “Option”) be, and it hereby is, granted to Lynn Kirkpatrick to purchase the
shares of the Company’s Common Stock set forth on the Notice of Stock Option Grant (the “Notice of Grant”)
attached hereby as Exhibit A pursuant to the Company’s 2016 Stock Incentive Plan and on the terms described in the
Notice of Grant;

 

RESOLVED
FURTHER, that, subject to the right of the Committee to review and adjust compensation as provided hereafter, so long as Lynn
Kirkpatrick shall continue to serve as Chief Executive Officer of the Company on a full time basis, Dr. Kirkpatrick’s salary
shall be fixed as follows: (i) until such time as the Company shall have received Qualifying Funding of $2 million, no salary
shall be payable to Dr. Kirkpatrick; (ii) at such time, if ever, as the Company shall have received Qualifying Funding of $2 million
or more, but less than $10 million, Dr. Kirkpatrick shall receive annual salary of $150,000; and (iii) at such time, if ever,
as the Company shall have received Qualifying Funding of $10 million or more, Dr. Kirkpatrick shall receive annual salary of $320,000;

 

RESOLVED
FURTHER, that the Compensation Committee shall review Dr. Kirkpatrick’s compensation at least annually and shall adjust
the same as it deems appropriate; provided that Dr. Kirkpatrick shall be entitled to such additional benefits as shall be generally
available to all other officers of the Company and, without the consent of Dr. Kirkpatrick, the salary and benefits to Dr. Kirkpatrick
shall not be reduced.

 

General

 

RESOLVED,
that the officers of the Company be, and each of them hereby is, authorized, directed and empowered to execute any instruments
or documents or amendments or supplements to such documents, or to do, or cause to be done, any and all other acts and things
as such officers, and each of them may, in their discretion, deem necessary or advisable and appropriate to carry out the purposes
of the foregoing resolutions.

[Signature
page follows]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the undersigned has executed this Action by Unanimous Written Consent as of the latest date set forth below.
This written consent may be executed in one or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same written consent.

 

	Directors:	 
	 	 
	Dated:
    January 15, 2016	/s/
    Bob Gower
	 	Bob
    Gower
	 	 
	Dated:
    January 15, 2016	/s/
    William Chang
	 	William
    Chang

 

    	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]